Pulmaquin

September 10, 2014November 6, 2015

Aradigm’s Novel Non-Cystic Fibrosis Bronchiectasis Treatment Granted Fast Track Status by FDA

Bronchiectasis, News

The pharmaceutical company Aradigm Corporation received Fast Track status for its lead product candidate, Pulmaquin, from the U.S. Food and Drug Administration. The drug, which is being studied for treatment of non-cystic ... Read more

August 5, 2014November 6, 2015

Aradigm Doses First Patient in Second Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis

Bronchiectasis, News

Aradigm Corporation announced the dosing of the first patient in a Phase III pivotal clinical trial that is testing Pulmaquin, an inhaled ciprofloxacin formula. ORBIT-4 is the second of two trials ... Read more

June 4, 2014November 6, 2015

Aradigm Receives $5 Million for the First Patient to Test Pulmaquin in Non-Cystic Fibrosis Bronchiectasis

Bronchiectasis, News

Aradigm Corporation has received a $5 million milestone payment from Grifols S.A. for dosing of the first patient in a phase III study of the ORBIT-3 (once-daily respiratory bronchiectasis inhalation ... Read more

May 22, 2014November 6, 2015

Non-Cystic Fibrosis Bronchiectasis Drug Pulmaquin Receives QIDP Designation From FDA

Bronchiectasis

Aradigm Corporation’s experimental therapy Pulmaquin, an inhaled antibiotic for the treatment of non-cystic fibrosis bronchiectasis, was recently given the Qualified Infectious Disease Product (QIDP) designation from the U.S. Food and Drug Administration (FDA). The ... Read more